



## ASX Announcement

17 July 2019

# Nunyara Granted Licence to Manufacture Medicinal Cannabis

### Highlights

- Nunyara granted licence to manufacture medicinal cannabis for extracts and tinctures of cannabis and cannabis resin
- Awaiting approval for Medicinal Cannabis Licence to cultivate and produce medicinal cannabis
- Board reviewing capital allocation requirements

### Manufacture Licence Update

**Elixinol Global Limited (Elixinol Global or the Company) (ASX:EXL; OTCQX:ELLXF)** is pleased to announce that its wholly owned subsidiary, Nunyara Pharma Pty Ltd (**Nunyara**), has been granted a licence to manufacture medicinal cannabis for extracts and tinctures of cannabis and cannabis resin, by the Australian Office of Drug Control (**ODC**).

Elixinol Global is still awaiting approval to receive its Medicinal Cannabis Licence which will allow the Company to cultivate and produce cannabis for medicinal purposes.

Stratos Karousos, the recently appointed Chief Executive Officer of Elixinol Global, said: “The granting of the Manufacture Licence is extremely exciting and we look forward to also being granted our Medicinal Cannabis Licence shortly which will complete our licence application process for Nunyara. The Board will continue with its review of capital allocation across all Elixinol Global businesses to deliver optimal value to our shareholders.”

### Review of capital requirements

The Board intends to review the capital required to support Nunyara’s ongoing growth in the Australian medicinal cannabis industry. Elixinol Global’s US CBD business continues to grow rapidly and provide extensive capital opportunities for the group to invest in. Further, the broader expansion of Elixinol Global’s CBD business in Europe remains a focus as the industry continues to evolve.

For more information please contact:

Ron Dufficy

Chief Financial Officer

[ron.dufficy@elixinolglobal.com](mailto:ron.dufficy@elixinolglobal.com)



### **About Elixinol Global**

Elixinol Global Limited (ASX:EXL; OTCQX:ELLXF) is a global leader in the cannabis industry, selling hemp-derived CBD dietary supplements, hemp food and wellness products, as well as the cultivation and manufacture of medicinal cannabis products.

Elixinol Global's businesses include:

- Elixinol LLC (Elixinol), a manufacturer and global distributor of industrial hemp based dietary supplement and skincare products, with operations based out of Colorado, USA;
- Hemp Foods Australia Pty Ltd (Hemp Foods Australia), a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products; and
- Nunyara Pharma Pty Ltd (Nunyara), founded in 2014 to participate in the emerging Australian medicinal cannabis market. Nunyara submitted licence applications for cultivation and manufacture to the Office of Drug Control in early 2018. The Manufacture Licence has been approved whilst the Medicinal Cannabis Licence is currently pending approval.

See more at [www.elixinolglobal.com](http://www.elixinolglobal.com)